A monoclonal antibody against cytochrome P-450 enhances mutagen activation of N-nitrosodimethylamine by mouse liver S9: studies on the mode of action

Carcinogenesis. 1987 Dec;8(12):1775-9. doi: 10.1093/carcin/8.12.1775.

Abstract

The effect of the monoclonal antibody MAb 2-66-3, directed against the major rat liver phenobarbital (PB)-induced cytochrome P-450 (P-450), on the S9-mediated mutagenicity of N-nitrosodimethylamine (DMN) in Salmonella typhimurium strain TA1530 was studied using liver S9 from PB-treated mice. This MAb enhanced approximately 2-fold S9-mediated mutagenicity of DMN but inhibited both its N-demethylation and N-denitrosation by 50%. Thus MAb-mediated enhancement of DMN mutagenesis does not result from altered activation/inactivation pathways, both known to involve P-450 isozymes. DMSO, a hydroxyl radical (HO.) scavenger and desferrioxamine, an inhibitor of HO.-dependent reactions, quenched the MAb-mediated enhancement of DMN mutagenesis, implicating the HO.-dependent activation of DMN to mutagenic species. As a mechanism, we propose that the binding of this MAb to P-450 isozyme implicated in DMN metabolism decreases the functional coupling between the reductase and the P-450 complex, leading to an increased electron flow from the reductase towards molecular oxygen to form reduced oxygen species (HO.) at the expense of the monooxygenase functions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal*
  • Cocarcinogenesis
  • Cytochrome P-450 Enzyme System / immunology*
  • Dimethyl Sulfoxide / pharmacology
  • Dimethylnitrosamine / pharmacology*
  • Isoenzymes / immunology
  • Liver / drug effects*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred DBA
  • Mutagenicity Tests
  • Phenobarbital / pharmacology
  • Salmonella typhimurium / drug effects

Substances

  • Antibodies, Monoclonal
  • Isoenzymes
  • Cytochrome P-450 Enzyme System
  • Dimethylnitrosamine
  • Dimethyl Sulfoxide
  • Phenobarbital